Peggy Scherle is the founder of Prelude Therapeutics. Prelude Therapeutics has raised $125M in total funding. Latest round: Growth.
Peggy Scherle, Ph.D., is the Chief Scientific Officer (CSO) at Prelude Therapeutics, a clinical-stage precision oncology company. She leads the discovery and development of small molecule therapies targeting cancer cell pathways. Scherle is based in Wilmington, Delaware, where the company is headquartered.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide